3D MEDICINES(01244) - 2023 - 年度业绩

Sales Performance - 3D Medicines Inc.'s first commercial product, Envida®, has accumulated sales exceeding RMB 1 billion[5] - The sales growth rate for Envida® in 2023 was 11.9%, surpassing the growth rate of sales and marketing expenses[5] Expenses - Sales and marketing expenses increased by 5.9% from RMB 357.7 million for the year ended December 31, 2022, to RMB 378.8 million for the year ended December 31, 2023[5]